Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 14;11(9):e37275.
doi: 10.2196/37275.

Bronchopulmonary Penetration of Isavuconazole in Pulmonary Transplant Recipients (PBISA01): Protocol for a Phase IV Clinical Trial With a Single Treatment Arm

Ignacio Darnaude-Ximénez #  1 , Antonio F Caballero-Bermejo #  1 , Belén Ruiz-Antorán  1 , Myriam Aguilar-Pérez  2 , Alicia Gómez-López  3 , Aranzazu Sancho-López  1 , Cristian García-Fadul  2 , Elena Diago-Sempere  1 , Manuel Valle Falcones  2 , Piedad Ussetti-Gil  2 , Cristina Avendaño-Solá  1 ; PBISA01-Study Group  3   4
Collaborators, Affiliations

Bronchopulmonary Penetration of Isavuconazole in Pulmonary Transplant Recipients (PBISA01): Protocol for a Phase IV Clinical Trial With a Single Treatment Arm

Ignacio Darnaude-Ximénez et al. JMIR Res Protoc. .

Abstract

Background: Aspergillosis is the most frequently observed invasive fungal disease (IFD) in lung transplant recipients. Isavuconazole (ISA) has shown a better safety profile and noninferiority to voriconazole in the treatment of patients with IFD.

Objective: The aim of this study is to describe the bronchopulmonary pharmacokinetic profile of oral ISA by analyzing the degree of penetration in the epithelial lining fluid and alveolar macrophages in patients receiving lung transplantation with a diagnosis of IFD.

Methods: A total of 12 patients aged ≥18 years receiving a lung transplant with an IFD diagnosis and indication for ISA treatment and follow-up bronchoscopy will be included in the study. After 5 days of treatment with ISA and before the treatment is discontinued, the patients will be randomized (1:1:1:1) to perform the scheduled bronchoscopy at various times after the administration of ISA (2, 4, 8, and 12 hours). In total, 4 blood samples will be obtained per patient: at 72 hours after treatment initiation, on the day of the bronchoscopy, at the time of the bronchoalveolar lavage (simultaneously), and at 7 days after treatment initiation, to analyze tacrolimus and ISA plasma levels. ISA concentrations will be measured in plasma, epithelial lining fluid, and alveolar macrophages by a high-performance liquid chromatography/UV coupled to fluorescence method.

Results: Enrollment for the PBISA01 trial began in October 2020 and was completed in October 2021. All samples will be analyzed once recruitment is complete, and the results are expected to be published in October 2022.

Conclusions: There are no clinical studies that analyze the bronchopulmonary penetration of ISA. Bronchoalveolar lavage performed routinely in the follow-up of lung transplant recipients constitutes an opportunity to analyze the bronchopulmonary penetration of ISA.

Trial registration: European Clinical Trials Register 2019-004240-30; www.clinicaltrialsregister.eu/ctr-search/trial/2019-004240-30/ES.

International registered report identifier (irrid): DERR1-10.2196/37275.

Keywords: alveolar macrophage; bronchiole; bronchoalveolar lavage; bronchoalveolar lavage fluid; bronchopulmonary; bronchopulmonary level; bronchoscopy; drug efficacy; epithelial lining fluid; fungal; fungus; infection; invasive fungal infections; isavuconazole; lung transplant; pharmaceutical; pharmacokinetic; triazoles.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Schedule of enrollment, interventions, and assessments. ELF: epithelial lining fluid.
See this image and copyright information in PMC

References

    1. Solé Amparo, Ussetti P. Mold infections in lung transplants. Article in Spanish. Rev Iberoam Micol. 2014 Oct;31(4):229–36. doi: 10.1016/j.riam.2014.07.001.S1130-1406(14)00064-3 - DOI - PubMed
    1. Kennedy CC, Razonable RR. Fungal infections after lung transplantation. Clin Chest Med. 2017 Sep;38(3):511–520. doi: 10.1016/j.ccm.2017.04.011. http://europepmc.org/abstract/MED/28797492 S0272-5231(17)30046-1 - DOI - PMC - PubMed
    1. Pilarczyk K, Haake N, Heckmann J, Carstens H, Haneya A, Cremer J, Jakob H, Pizanis N, Kamler M. Is universal antifungal prophylaxis mandatory in adults after lung transplantation? a review and meta-analysis of observational studies. Clin Transplant. 2016 Dec;30(12):1522–1531. doi: 10.1111/ctr.12854. - DOI - PubMed
    1. Husain S, Bhaskaran A, Rotstein C, Li Y, Bhimji A, Pavan R, Kumar D, Humar A, Keshavjee S, Singer LG. A strategy for prevention of fungal infections in lung transplantation: role of bronchoalveolar lavage fluid galactomannan and fungal culture. J Heart Lung Transplant. 2018 Jul;37(7):886–894. doi: 10.1016/j.healun.2018.02.006.S1053-2498(18)31356-1 - DOI - PubMed
    1. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann R J M, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux J, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018 May;24 Suppl 1:e1–e38. doi: 10.1016/j.cmi.2018.01.002. https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(18)30051-X S1198-743X(18)30051-X - DOI - PubMed

LinkOut - more resources